Helicos Biosciences, the Cambridge, MA-based maker of genetic analysis tools, said today it has reached an agreement to raise $18 million in a private offering of common stock and warrants to buy shares. Helicos (NASDAQ: [[ticker:HLCS]]) didn’t say how much longer the cash infusion will allow it to operate. The company reported a net loss in the third quarter of $11.4 million, and about $22.8 million of cash and investments left at the end of September.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
